[go: up one dir, main page]

SG11201908721TA - Conjugation of a cytotoxic drug with bis-linkage - Google Patents

Conjugation of a cytotoxic drug with bis-linkage

Info

Publication number
SG11201908721TA
SG11201908721TA SG11201908721TA SG11201908721TA SG 11201908721T A SG11201908721T A SG 11201908721TA SG 11201908721T A SG11201908721T A SG 11201908721TA SG 11201908721T A SG11201908721T A SG 11201908721TA
Authority
SG
Singapore
Prior art keywords
street
hangzhou
zhejiang
bildg
international
Prior art date
Application number
Inventor
Robert Yongxin Zhao
Yuanyuan Huang
Qingliang Yang
Shun Gai
Hangbo Ye
Linyao Zhao
Chengyu Yang
Yifang Xu
Huihui Guo
Minjun Chao
Qianqian Tong
Wenjun Li
Xiang Cai
Xiaomai Zhou
Hongsheng Xie
Junxiang Jia
Haifeng Zhu
Zhixiang Guo
Shuihong Gao
Chunyan Wang
Chen Lin
Yanlei Yang
Zhicang Ye
Jie Peng
Jun Xu
Xiaotao Zuo
Qingyu Su
Original Assignee
Hangzhou Dac Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hangzhou Dac Biotech Co Ltd filed Critical Hangzhou Dac Biotech Co Ltd
Publication of SG11201908721TA publication Critical patent/SG11201908721TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6831—Fungal toxins, e.g. alpha sarcine, mitogillin, zinniol or restrictocin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 11 October 2018 (11.10.2018) WIPO I PCT 0111111010 0111 °nolo OH H imomiono oimIE (10) International Publication Number WO 2018/185526 Al (51) International Patent Classification: C07D 417/14 (2006.01) A61P 31/00 (2006.01) (21) International Application Number: PCT/IB2017/051977 (22) International Filing Date: 06 April 2017 (06.04.2017) (25) Filing Language: English (26) Publication Language: English (71) Applicant: HANGZHOU DAC BIOTECH CO., LTD [CN/CN]; Building 12, ZhengTaiZhongZi Tech. Park, No. 260 Sixth Street, HEDA, Hangzhou, Zhejiang 310018 (CN). (72) Inventors: ZHAO, Robert Yongxin; 7Loring Street, 7Loring Street, Lexington, Massachusetts 02421 (US). HUANG, Yuanyuan; Room 401, Building 12, No. 260 Sixth Street, Hangzhou, Zhejiang 310018 (CN). YANG, Qingliang; Room 401, Building 12, No. 260 Sixth Street, Hangzhou, Zhejiang 310018 (CN). GAL Shun; Rm 303, Bildg 12, No. 260 Sixth Street, Hangzhou, Zhejiang 310018 (CN). YE, Hangbo; Rm 402, Bldge 12, No. 260 Sixth Street, Hangzhou, Zhejiang 310018 (CN). ZHAO, Linyao; Rm 403, Bldge 12, No. 260 Sixth Street, Hangzhou, Zhe- jiang 310018 (CN). YANG, Chengyu; Rm 402, Bldge 12, No. 260 Sixth Street, Hangzhou, Zhejiang 310018 (CN). XU, Yifang; Rm 402, Bldg 12, No. 260 Sixth Street, Hangzhou, Zhejiang 310018 (CN). GUO, Huihui; Rm 304, Bldg 12, No. 260 Sixth Street, Hangzhou, Zhejiang 310018 (CN). CHAO, Minjun; Rm 304, Bildg 12, No. 260 Sixth Street, Hangzhou, Zhejiang 310018 (CN). TONG, Qian- qian; Rm 302, Bildg 12, No. 260 Sixth Street, Hangzhou, Zhejiang 310018 (CN). LI, Wenjun; Rm 405, Bildg 12, No. 260 Sixth Street, Hangzhou, Zhejiang 310018 (CN). CAI, Xiang; Rm 304, Bildg 12, No. 260 Sixth Street, Hangzhou, Zhejiang 310018 (CN). ZHOU, Xiaomai; Rm 2006, Bildg 12, No. 260 Sixth Street, Hangzhou, Zhejiang 310018 (CN). XIE, Hongsheng; Rm 2005, Bildg 12, No. 260 Sixth Street, Hangzhou, Zhejiang 310018 (CN). JIA, Junxiang; Rm 301, Bildg 12, No. 260 Sixth Street, Hangzhou, Zhe- jiang 310018 (CN). ZHU, Haifeng; Rm 305, Bildg 12, No. 260 Sixth Street, Hangzhou, Zhejiang 310018 (CN). GUO, Zhixiang; Rm 102,Bildg 12, No. 260 Sixth Street, Hangzhou, Zhejiang 310018 (CN). GAO, Shuihong; Rm 305, Bildg 12, No. 260 Sixth Street, Hangzhou, Zhejiang 310018 (CN). WANG, Chunyan; Rm 305, Bildg 12, No. 260 Sixth Street, Hangzhou, Zhejiang 310018 (CN). LIN, Chen; Rm 301, Bildg 12, No. 260 Sixth Street, Hangzhou, Zhejiang 310018 (CN). YANG, Yanlei; Rm 103, Bildg 12, No. 260 Sixth Street, Hangzhou, Zhejiang 310018 (CN). YE, Zhicang; Rm 303, Bildg 12, No. 260 Sixth Street, Hangzhou, Zhejiang 310018 (CN). PENG, Jie; Rm 104, Bildg 12, No. 260 Sixth Street, Hangzhou, Zhejiang 310018 (CN). XU, Jun; Rm 301, Bildg 12, No. 260 Sixth Street, Hangzhou, Zhejiang 310018 (CN). ZUO, Xiaotao; Rm 402, Building 12, 260 Sixth Street, HEDA, Hangzhou, Zhejiang 310018 (CN). SU, Qingyu; Rm 303, Building 12, 260 Sixth Street, HEDA, Hangzhou, Zhejiang 310018 (CN). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to the identity of the inventor (Rule 4.170) as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) of inventorship (Rule 4.17(iv)) Published: with international search report (Art. 21(3)) 1-1 (54) Title: CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE (57) : What provided is the conjugation of cytotoxic to a cell-binding molecule with a bis-linker(dual-linker) as shown in 0 Formula (I). It provides bis-linkage methods of making a conjugate of a cytotoxic drug molecule to a cell-binding agent in a specific \" manner. It also relates to application of the conjugates for the treatment of a cancer, or an autoimmune disease, or an infectious disease. C
SG11201908721T 2017-04-06 2017-04-06 Conjugation of a cytotoxic drug with bis-linkage SG11201908721TA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2017/051977 WO2018185526A1 (en) 2017-04-06 2017-04-06 Conjugation of a cytotoxic drug with bis-linkage

Publications (1)

Publication Number Publication Date
SG11201908721TA true SG11201908721TA (en) 2019-10-30

Family

ID=63712416

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201908721T SG11201908721TA (en) 2017-04-06 2017-04-06 Conjugation of a cytotoxic drug with bis-linkage

Country Status (16)

Country Link
US (4) US20200069814A1 (en)
EP (1) EP3606922A4 (en)
JP (2) JP7218919B2 (en)
KR (6) KR102655301B1 (en)
CN (1) CN110621673A (en)
AU (1) AU2017408164B2 (en)
BR (1) BR112019020049A2 (en)
CA (1) CA3058712C (en)
CL (1) CL2019002858A1 (en)
EA (1) EA201992081A1 (en)
IL (1) IL269713B2 (en)
MX (1) MX2019011957A (en)
NZ (1) NZ757008A (en)
PH (1) PH12019502278A1 (en)
SG (1) SG11201908721TA (en)
WO (1) WO2018185526A1 (en)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11873281B2 (en) 2012-07-12 2024-01-16 Hangzhou Dac Biotech Co., Ltd. Conjugates of cell binding molecules with cytotoxic agents
EP3348280A1 (en) 2012-07-12 2018-07-18 Hangzhou Dac Biotech Co., Ltd Conjugates of cell binding molecules with cytotoxic agents
ITUB20153803A1 (en) 2015-09-22 2017-03-22 Gd Spa Machine for the production of cartridges for electronic cigarettes.
JP7011764B2 (en) 2016-07-07 2022-01-27 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー Antibody adjuvant complex
ES2885003T3 (en) 2016-09-02 2021-12-13 Cyclerion Therapeutics Inc Bicyclic fused SGC stimulators
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
IL317268A (en) 2017-12-31 2025-01-01 Hangzhou Dac Biotech Co Ltd A conjugate of a tubulysin analog with branched linkers
CA3105541A1 (en) * 2018-07-05 2020-01-09 Hangzhou Dac Biotech Co., Ltd Cross-linked pyrrolobenzodiazepine dimer (pbd) derivative and its conjugates
JP2022504745A (en) * 2018-10-12 2022-01-13 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ． Conjugated conjugate containing 2,3-diaminosuccinyl group
WO2020081493A1 (en) 2018-10-16 2020-04-23 Molecular Templates, Inc. Pd-l1 binding proteins
BR112021014471A2 (en) * 2019-01-31 2021-09-21 Hangzhou Dac Biotech Co., Ltd CONJUGATED COMPOUND CONNECTED TO THE SIDE CHAIN. SIDE CHAIN CONNECTION COMPOUND, SIDE CHAINS Q1 AND Q2, D (AMANITA TOXIN STRUCTURE), W, L1, L2, V1 AND V2, COMPOUND, CELL BINDING AGENT/MOLECULE, T CELL BINDING MOLECULE, CELL OF TUMOR, PHARMACEUTICAL COMPOSITION, AND, CHEMOTHERAPEUTIC AND SYNERGISTIC AGENTS
EP3937984A1 (en) 2019-03-15 2022-01-19 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
KR20220008869A (en) 2019-05-14 2022-01-21 누베이션 바이오 인크. Anticancer Nuclear Hormone Receptor-Targeting Compounds
WO2020229878A1 (en) * 2019-05-15 2020-11-19 Universidad De La Frontera Composition for topical use for photodynamic therapy
CN110054580A (en) * 2019-05-22 2019-07-26 苏州百灵威超精细材料有限公司 The preparation method of 4- (4-N- maleimide phenyl) butyric acid hydrazides hydrochloride
PH12021500050A1 (en) * 2019-06-24 2022-05-02 Hangzhou Dac Biotech Co Ltd A conjugate of a cytotoxic agent to a cell binding molecule with branched linkers
JP2022540638A (en) * 2019-07-12 2022-09-16 コントラフェクト コーポレイション Therapeutic protein preparations containing antibodies and uses thereof
WO2021055816A1 (en) 2019-09-18 2021-03-25 Molecular Templates, Inc. Pd-l1 binding molecules comprising shiga toxin a subunit scaffolds
KR20220103961A (en) * 2019-11-11 2022-07-25 씨스톤 파마슈티컬즈 (쑤저우) 컴퍼니 리미티드 Pharmaceutical combinations and uses thereof
TW202131930A (en) 2019-11-13 2021-09-01 美商諾維雪碧歐公司 Anti-cancer nuclear hormone receptor-targeting compounds
MX2022007353A (en) 2019-12-17 2022-09-19 Univ Texas NOVEL DDR1 ANTIBODIES AND THEIR USES.
JP2023509991A (en) * 2020-01-13 2023-03-10 シンアフィックス ビー．ブイ． Conjugates of antibodies and immune cell engagers
WO2021144313A1 (en) * 2020-01-13 2021-07-22 Synaffix B.V. Via cycloaddition bilaterally functionalized antibodies
WO2021144314A1 (en) * 2020-01-13 2021-07-22 Synaffix B.V. Via cycloaddition bilaterally functionalized antibodies
CN111297876B (en) * 2020-01-16 2021-04-27 武汉理工大学 A kind of celecoxib micelle and honokiol micelle drug combination controlled release system and preparation method thereof
WO2021143826A1 (en) * 2020-01-17 2021-07-22 信达生物制药(苏州)有限公司 Recombinant anti-programmed cell death protein 1 and anti-cluster of differentiation antigen 137 bispecific antibody preparation and use thereof
CA3108168A1 (en) * 2020-02-05 2021-08-05 Yue Zhang Conjugates of cell-binding molecules with cytotoxic agents
CN111233949A (en) * 2020-02-10 2020-06-05 天津科技大学 A kind of ganglioside GM3 and/or its analog, synthetic method and application
CN113925973A (en) * 2020-07-14 2022-01-14 辽宁中健医药科技有限公司 Polypeptide coupled drug, preparation method and application thereof
GB202011993D0 (en) 2020-07-31 2020-09-16 Adc Therapeutics Sa ANTI-IL 13Ra2 antibodies
JP2023540526A (en) 2020-09-04 2023-09-25 ノヴァロック バイオセラピューティクス， リミテッド Nectin-4 antibody and its use
WO2022147148A1 (en) * 2020-12-30 2022-07-07 Trellis Bioscience, Inc. Therapeutic protein formulations comprising anti-dnabii antibodies and uses thereof
EP4308242A1 (en) 2021-03-17 2024-01-24 Molecular Templates, Inc. Pd-l1 binding proteins comprising shiga toxin a subunit scaffolds and cd8+ t cell antigens
WO2022204184A1 (en) 2021-03-23 2022-09-29 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
MX2023011517A (en) * 2021-03-29 2023-11-28 Od Therapeutics Ltd Protein-macromolecule conjugates and methods of use thereof.
CN115177740A (en) * 2021-04-01 2022-10-14 安升（上海）医药科技有限公司 Construction method and application of nucleic acid self-assembly mediated ADC (azodicarbonamide) medicament
JP2024516024A (en) 2021-05-03 2024-04-11 ニューベイション・バイオ・インコーポレイテッド Anti-cancer nuclear hormone receptor targeting compounds
CN113603750A (en) * 2021-08-30 2021-11-05 湖南三太药业有限公司 Method for synthesizing nafarelin in full liquid phase
EP4426727A2 (en) 2021-11-03 2024-09-11 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody
CN114213540B (en) * 2022-02-22 2022-07-01 北京大学人民医院 Antibody composition for immune typing of myeloid tumor and application thereof
CN119947755A (en) * 2022-07-29 2025-05-06 宾夕法尼亚大学理事会 Lymphatic targeting anticoagulants for preventing lymphatic thrombosis
CN119431181A (en) * 2023-08-04 2025-02-14 泰诚思(上海)生物医药有限公司 Bis-ene linker, linker-drug conjugate, antibody-drug conjugate and use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2173150C (en) * 1993-10-01 2004-11-30 Kyoichi Sakakibara Novel peptide derivatives
ES2784829T3 (en) * 2009-04-08 2020-10-01 Faulstich Heinz Dr Amatoxin-provided therapeutic cell surface-binding components designed for tumor therapy
WO2012143497A2 (en) * 2011-04-21 2012-10-26 Bayer Intellectual Property Gmbh Novel binder-drug conjugates (adcs) and their use
WO2013085925A1 (en) * 2011-12-05 2013-06-13 Igenica, Inc. Antibody-drug conjugates and related compounds, compositions, and methods
WO2013132268A1 (en) * 2012-03-09 2013-09-12 Ucl Business Plc Chemical modification of antibodies
HK1208216A1 (en) 2012-05-15 2016-02-26 Concortis Biosystems, Corp Drug-conjugates, conjugation methods, and uses thereof
FR3008408B1 (en) * 2013-07-11 2018-03-09 Mc Saf NOVEL ANTIBODY-MEDICAMENT CONJUGATES AND THEIR USE IN THERAPY
WO2015151078A2 (en) * 2015-06-15 2015-10-08 Suzhou M-Conj Biotech Co., Ltd Hydrophilic linkers for conjugation
CN108449940B (en) * 2015-07-12 2021-06-08 杭州多禧生物科技有限公司 Conjugated bridging linkers to cell-binding molecules
US10292961B2 (en) * 2015-07-15 2019-05-21 Hangzhou Dac Biotech Co., Ltd. Disulfur bridge linkers for conjugation of a cell-binding molecule
EP3411074A4 (en) * 2016-02-04 2019-09-04 Suzhou M-conj Biotech Co., Ltd. Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof
NZ744936A (en) * 2016-04-20 2022-01-28 Hangzhou Dac Biotech Co Ltd Derivatives of amanita toxins and their conjugation to a cell binding molecule

Also Published As

Publication number Publication date
BR112019020049A2 (en) 2020-05-12
JP2023061938A (en) 2023-05-02
JP2020516595A (en) 2020-06-11
KR102739597B1 (en) 2024-12-06
IL269713A (en) 2019-11-28
AU2017408164B2 (en) 2021-02-25
US20200069814A1 (en) 2020-03-05
KR20210122319A (en) 2021-10-08
WO2018185526A1 (en) 2018-10-11
KR20190141660A (en) 2019-12-24
JP7689751B2 (en) 2025-06-09
NZ757008A (en) 2022-04-29
IL269713B2 (en) 2023-08-01
CN110621673A (en) 2019-12-27
CL2019002858A1 (en) 2020-09-04
KR102698575B1 (en) 2024-08-26
EP3606922A1 (en) 2020-02-12
IL269713B1 (en) 2023-04-01
AU2017408164A1 (en) 2019-10-03
CA3058712C (en) 2023-04-18
KR102655301B1 (en) 2024-04-08
CA3058712A1 (en) 2018-10-11
KR20210125094A (en) 2021-10-15
US20210393790A1 (en) 2021-12-23
KR20230074284A (en) 2023-05-26
EP3606922A4 (en) 2021-03-03
KR20210122318A (en) 2021-10-08
KR20230074285A (en) 2023-05-26
EA201992081A1 (en) 2020-01-21
JP7218919B2 (en) 2023-02-09
MX2019011957A (en) 2019-11-07
US20210369855A1 (en) 2021-12-02
PH12019502278A1 (en) 2020-07-06
US20230001001A1 (en) 2023-01-05

Similar Documents

Publication Publication Date Title
SG11201908721TA (en) Conjugation of a cytotoxic drug with bis-linkage
SG11201807652SA (en) Derivatives of amanita toxins and their conjugation to a cell binding molecule
SG11201807472TA (en) Amanitin conjugates
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201811448RA (en) Dihydropyranopyrimidines for the treatment of viral infections
SG11201810485SA (en) Substituted carbonucleoside derivatives useful as anticancer agents
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201811150WA (en) Ev-mediated delivery of binding protein-small molecule conjugates
SG11201906386XA (en) Combination therapy involving diaryl macrocyclic compounds
SG11201806594QA (en) Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof
SG11201806419RA (en) Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates
SG11201809830WA (en) Selective reduction of cysteine-engineered antibodies
SG11201903287PA (en) Anti-respiratory syncytial virus antibodies, and methods of their generation and use
SG11201408605UA (en) Methods for biodegradable derivatization of cellulosic surfaces
SG11201907693VA (en) Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof
SG11201807185UA (en) Modified hyaluronic acid, method for making same and uses thereof
SG11201909841RA (en) Antitumoral compounds
SG11201811205PA (en) Polysiloxane based aerogels
SG11201909680UA (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
SG11201903076QA (en) Carbamoyl phenylalaninol compounds and uses therof
SG11201811335UA (en) Quinolinyldiamido transition metal complexes, production and use thereof
SG11201900361RA (en) Methods of treating prostate cancer
SG11201906313SA (en) A polypeptide linker for preparing multispecific antibodies
SG11201805149XA (en) Compositions comprising 15-hepe and methods of using the same
SG11201407261XA (en) Oligonucleotide chelate complex methods